Whitepapers
The Strategic Narrative Thread: Connecting brand messaging and execution
Whitepaper
Jul 12, 2023
A Practical Guide to Segmentation: What, who, why, and how?
Whitepaper
Jul 5, 2023
Scenario-based Strategy in Tumultuous Times: How pharma executives can conquer uncertainty
Whitepaper
Jun 28, 2023
Overcoming Challenges in Demonstrating the Value of Drugs for Treating Rare Diseases
Whitepaper
May 31, 2023
Facing Up to the Challenges of EU Joint Clinical Assessments
Whitepaper
Mar 31, 2023
Do You Really Know How Your Market Works?
Whitepaper
Jan 18, 2023
The story behind the numbers: How burden of illness studies add value to HTA submissions
Whitepaper
Dec 5, 2022
Medical Strategy: How Medical Affairs Creates Alignment and Demonstrates Value
Whitepaper
Nov 10, 2022
Optimizing Launch Commercialization of Cell and Gene Therapies: Charting a Path to Success
Whitepaper
Nov 9, 2022
Comparing Outcomes Pre- and Post-Cancer Drugs Fund
Whitepaper
Oct 19, 2022
Comparing Outcomes Pre- and Post-Cancer Drugs Fund
In this paper we look at the 18 appraisals that had entered and exited the CDF between June 2016 and April 2022 to provide insights on what manufacturers can expect from the CDF and to understand whether the CDF is operating optimally to resolve genuine uncertainty in submissions.
Whitepaper
Oct 19, 2022